Caribou Biosciences (CRBU) Non Operating Income (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Non Operating Income data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Non Operating Income fell 59.1% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.1 million (down 113.15% YoY) and the FY2025 annual result came in at -$331000.0, down 101.89% from the prior year.
• Non Operating Income declined to $1.2 million in Q1 2026 per CRBU's latest filing, from $1.4 million in the prior quarter.
• Across five years, Non Operating Income topped out at $5.8 million in Q2 2024 and bottomed at -$6.5 million in Q2 2025.
• The 5-year median for Non Operating Income is $3.1 million (2023), against an average of $2.3 million.
• The widest annual swing landed in 2022, when Non Operating Income surged 10931.25%; it then sank 212.34% in 2025.
• Tracing CRBU's Non Operating Income over 5 years: stood at $3.7 million in 2022, then fell by 14.46% to $3.1 million in 2023, then advanced by 7.86% to $3.4 million in 2024, then plunged by 58.09% to $1.4 million in 2025, then declined by 15.55% to $1.2 million in 2026.
• Per Business Quant, the three latest CRBU Non Operating Income figures stand at $1.2 million (Q1 2026), $1.4 million (Q4 2025), and $1.9 million (Q3 2025).

Peer Comparison